Advice
following a full submission
lenalidomide (Revlimid®) is accepted for use within NHS Scotland.
Indication under review: for the treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.
Lenalidomide therapy significantly increased the proportion of patients achieving sustained red blood cell transfusion independence compared with best supportive care. However, there was no significant improvement in overall survival.
Download detailed advice149KB (PDF)
Medicine details
- Medicine name:
- lenalidomide (Revlimid)
- SMC ID:
- 942/14
- Indication:
- For the treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.
- Pharmaceutical company
- Celgene Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 10 March 2014